Incyte Corporation Equity-NMS: INCY

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Error in Fetching Data, Please retry later.
Previous close :$62.33
Open :$62.06
Today's high :$62.89
Today's low :$61.45
52W low :$50.3498
52W high :$83.95
EPS(TTM): :0.15
Shares O/S :193.52 M
Market cap :12.09 B

Compare with Other Stocks

Stocks Price 1D PE Market Cap
Incyte Corporation $62.46 +0.3% 415.53 12.09B

Frequently Asked Questions

What is the share price of Incyte Corporation today?

Incyte Corporation (INCY) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.